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Bern, SwitzerlandStent thrombosis (ST) has been a shortcoming of coronary
artery stents since their inception. However, the advent of
dual antiplatelet therapy (DAPT), improved stent plat-
forms, and emphasis on optimal stent implantation have
led to event rates of 1% to 2% in contemporary practice.
According to its timing relative to the index procedure,
ST can be categorized into early (i.e., occurring 30 days),
late (>30 days), or very late (>1 year) ST. After the
“European Society of Cardiology ﬁrestorm,” when safety
concerns emerged regarding the use of early-generation
drug-eluting stents (DES), attention shifted to late and
very late ST. Consequently, it may be easy to overlook the
fact that the highest density of ST events occur within
the ﬁrst 30 days after percutaneous coronary intervention
(PCI) (Fig. 1). For example, in the Dutch ST Registry (437/
21,009 ST), 73% of ST events were early, whereas only 27%
were late (1).
See page 2510
The causes of ST can be broadly categorized into patient,
lesion, and procedure-related factors (Table 1). Although
premature discontinuation of antiplatelet therapy is one of
the strongest predictors of early ST (1), the majority of early
ST occur while patients are still taking DAPT. For example,
in one of the largest ST registries to date, 88% of patients
who had an early ST were still taking DAPT at the time of
the event (1). Several intracoronary imaging studies that
used predominantly intravascular ultrasound (IVUS) have
assessed procedural factors associated with early ST. Stent
underexpansion and inﬂow or outﬂow obstruction were
the most consistent variables associated with early ST
(2–6). Other variables, such as stent malapposition, were
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HORIZONS-AMI (Harmonizing Outcomes with Revas-
cularization and Stents in Acute Myocardial Infarction)
found that smaller ﬁnal lumen area and inﬂow or outﬂow
disease were predictive of early ST but that stent malap-
position was not predictive (6), ﬁndings that corroborated
a previous report by Fujii et al. (5). Conversely, other in-
vestigators have found that stent malapposition is associated
with early ST (4).
Stent implantation in the setting of acute coronary syn-
dromes (ACS) is associated with a higher risk for ST
compared with that in patients with stable angina (7). In the
HORIZONS-AMI trial, the rate of early ST was 2.5%,
which was higher than the 1.4% early ST rate reported in
another large trial of moderate- to high-risk patients pre-
senting with non-STEMI (7,8). Both rates of early ST
were higher than the 0.1% to 0.6% rates of early ST reported
from the randomized, controlled trials (RCTs) of DES in
patients with stable coronary artery disease. However, more
recent ACS studies have shown that the rates of early
ST are lower with new generation devices. For example, in
two recent STEMI RCTs that used newer-generation
DES, namely EXAMINATION (Clinical Evaluation of
the Xience-V Stent in Acute Myocardial Infarction) and
COMFORTABLE-AMI (Comparison of Biolimus Eluted
From An Erodible Stent Coating With Bare Metal Stents
in Acute ST-Elevation Myocardial Infarction), rates of early
deﬁnite ST were 0.4% and 0.9%, as compared with 1.6%
and 1.8% with bare-metal stents (BMS), respectively (9,10).
Factors responsible for these improvements may relate to
more biocompatible polymers and lower strut thickness of
contemporary devices (11). Biocompatible polymers have
been shown to reduce thrombogenicity relative to BMS in
the early phase (12).
In this issue of the Journal, Nakano et al. (13) investigated
the histopathologic features of early ST in patients pre-
senting with ACS. The authors dichotomized 59 patients
recruited from their autopsy stent registry who presented
with ACS and died within 30 days of stent implantation into
an early ST group (n ¼ 34) and a control group (n ¼ 25).
Causes of death in the control group were cardiac (stent-
related, n ¼ 3; non–stent-related, n ¼ 17), non-cardiac
(n ¼ 3), and unknown (n ¼ 2). The main ﬁndings were
that necrotic core prolapse, intra-stent medial tear, and
incomplete stent apposition were independent predictors of
early ST. Although balloon inﬂation pressures at the time of
stent implantation are not available, one can speculate that
necrotic core prolapse and medial tear may have been
associated with high balloon inﬂation pressure, whereas
incomplete apposition may have been more likely to occur
with low balloon inﬂation pressures during PCI.
An alternative explanation is that the size and extent of the
underlying ruptured plaque and necrotic core may incur a
higher thrombogenicity. This hypothesis is supported by the
larger thrombus burden and higher rates of plaque rupture
observed in the early ST group of the present study.
Figure 1 Early Versus Late Stent Thrombosis
Overall rates of stent thrombosis (ST) in a recent all-comer registry (1) and acute
coronary syndrome trials (9,10,18,19) categorized according to timing of pre-
sentation, that is, early (30 days) or late (>30 days) ST. Rates of deﬁnite ST are
reported except for TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis In
Myocardial Infarction 38) (18), in which rates of deﬁnite or probable ST are shown.
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2522A novel ﬁnding of this study is that medial tear, specif-
ically the length of medial tear, is associated with ST. This
observation has not previously been reported to be associated
with early ST because both IVUS and optical coherence
tomography lack the resolution to detect it, particularly
behind stent struts. It may indicate that severe stent-
mediated arterial injury incurs not only more inﬂammation
but also a higher thrombogenicity, with the attendant risk
of thrombotic stent occlusion.
Some limitations are noteworthy. First, this is a case-
control autopsy series and not a clinical study, resulting in
a highly selected population. Second, stent underexpansion,
which was one of the most consistent predictors for early
ST in studies that used IVUS, could not be evaluated
because of the shrinkage of non-stented coronary arteries
during ﬁxation and histologic processing. Third, it would
have been interesting to correlate the balloon inﬂation
pressures during index stent implantation between the
medial tear and the non-medial tear groups to conﬁrm
whether or not this mechanism was responsible. Finally, no
information on the status of antiplatelet therapy is provided
for 16 of 34 (47%) patients with early ST. This is relevant
because the argument for the aforementioned pathological
variables as causative for the early ST events would be
further strengthened if patients were taking DAPT at the
time of the ST event.
What are the implications of this study? First, this study
conﬁrms previous observations that procedural and lesion
factors are causally related to early ST. It emphasizes the
potential role of intracoronary imaging in describing the
underlying plaque, quantifying the lesion extent, and
assessing procedural results in terms of stent apposition(13,14). The recent ADAPT-DES (Assessment of Dual
Antiplatelet Therapy with Drug-Eluting Stents) study re-
ported that IVUS-guided PCI was associated with a 60%
relative risk reduction in deﬁnite or probable ST at 1 year,
with an impact apparent in the early period as compared
with angiography guided PCI (15). The beneﬁts of IVUS in
this study were particularly pronounced among patients
presenting with ACS, with a gradient of beneﬁt observed in
patients with STEMI proﬁting most, followed by patients
with non-STEMI, unstable angina, and stable angina,
respectively (15). However, no RCTs comparing intra-
coronary imaging-guided PCI with angiography-guided
PCI exist to date, precluding a universal application in
clinical practice.
Second, the study points to potential improvements of
early clinical outcomes related to stent design. Intriguingly,
the concept behind the use of self-expanding stents in the
setting of primary PCI to overcome stent malapposition is
of interest in the context of the present study. Deep pene-
tration of stent struts into the necrotic core and medial
tear could theoretically be obviated with (less traumatic) self-
expanding stents. In practice, however, a real-world registry
of patients with STEMI who were treated with self-
expanding stents reported an early ST rate of 2.5%, which
suggests that further reﬁnements are needed (16). The
ﬁnding of stent malapposition as well as a higher thrombus
burden in the early ST group of the present study also
support the notion that mesh-covered stents may provide
therapeutic beneﬁt by excluding thrombus and necrotic core
prolapse, thereby potentially mitigating the risk of early
ST in patients with STEMI (14). Notwithstanding, new-
generation DES are the current stents of choice in the
setting of primary PCI. Indeed, a pooled analysis of two
recent STEMI studies demonstrated a 62% relative risk
reduction in the rate of early deﬁnite ST with new genera-
tion DES as compared with BMS (17), which suggests that
these devices are at least as safe as BMS.
Third, intrastent medial tear appeared to be an important
component of early ST in the present study, which is a
novel ﬁnding not reported before in clinical or pathological
studies. Of note, most modern stents used in present-day
PCI have thinner struts as compared with early-generation
devices investigated here, which predispose to less arterial
injury and more rapid endothelialization (11). Therefore,
arterial injury and medial tears may be less of an issue in the
current era. However, the results may be pertinent to the
current generation of bioresorbable scaffolds, which have
thicker struts and require more extensive lesion preparation
(11). In this context, it is noteworthy to mention the
growing interest to evaluate completely bioresorbable scaf-
folds in the setting of ACS because they may provide long-
term advantages in terms of arterial healing in the context of
underlying necrotic core.
Fourth, thrombus burden continues to play a key role in
the pathogenesis of early ST. This stresses the importance
of potent antiplatelet and anticoagulant strategies. For
Table 1
Mechanisms of Early and (Very) Late Stent
Thrombosis on the Basis of Autopsy,
Intracoronary Imaging, and Clinical Studies
Factor Early Late
Autopsy studies
Necrotic core prolapse* þþþ
Incomplete stent apposition* þþþ
Intrastent medial tear* þþþ
Thrombus burden* þ
Plaque rupture* þ
Neoatherosclerosis þþþ
Stent polymer (SIBS, PEVA, PBMA) þþ
Inﬂammation/hypersensitivity þþþ
Incomplete reendothelialization þþ þþþ
Intracoronary imaging studies
Stent underexpansion þþþ þþþ
Incomplete stent apposition þ þþþ
Intimal dissection þþþ
Inﬂow/outﬂow obstruction þþþ þþ
Tissue prolapse þþ
Clinical studies
Acute coronary syndrome/ST-segment
elevation myocardial infarction
þþþ þþ
Renal failure þþ þþ
Diabetes mellitus þ þþ
Impaired left ventricular function þ þ
Stent undersizing þþþ þþþ
Premature cessation of dual antiplatelet therapy þþþ þ
Thrombus burden þþ þþ
Prior brachytherapy þþ
Malignancy þ þþ
Peripheral artery disease þ
Bifurcation lesions þ þ
Chronic total occlusion þ
TIMI ﬂow after PCI þþ
*Autopsy variables described in the study by Nakano et al. (13). Intrastent medial tear is a novel
variable, hitherto not described to be associated with early ST.
PBMA ¼ poly n-butyl methacrylate; PCI ¼ percutaneous coronary intervention; PEVA ¼ poly-
ethylene-co-vinyl acetate; SIBS ¼ poly(styrene-b-isobutylene-b-styrene); ST ¼ stent thrombosis;
TIMI ¼ Thrombolysis In Myocardial Infarction.
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2523example, a 56% relative risk reduction in early ST was
recently observed among prasugrel-treated patients under-
going primary PCI as compared with clopidogrel-treated
patients (18). Similarly, a 40% relative risk reduction in
subacute ST was observed among ticagrelor-treated patients
as compared with clopidogrel-treated patients with ACS
undergoing stent implantation (19). The overall adoption of
novel P2Y12 inhibitors is growing in primary PCI and may
be complemented by intravenous agents such as cangrelor in
the future (20). Moreover, catheter-based thrombus aspira-
tion continues to deserve consideration in selected patients.
For example, a trend toward a reduced risk of early ST was
observed in the recent TASTE (Thrombus Aspiration in
ST-Elevation Myocardial Infarction in Scandinavia) trial
(p ¼ 0.06) (21).
The study by Nakano et al. (13) appropriately directs our
focus to the pathophysiologic mechanisms of early (rather
than late) ST and reinforces the importance of proceduraland lesion factors in mitigating against early ST during
ACS. Moreover, the present study has unveiled new
mechanistic insights into the etiology of early ST. Studies
such as these are needed to reﬁne and hone stent technology
and implantation, which may help to further lower rates of
early ST in the future. However, with current rates of early
ST in STEMI approaching <1%, the future may already be
here (10).
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